NASDAQ · BDTX
Healthcare · Biotechnology
$1.88
Up+$0.01 (+0.53%)
Updated Oct 2, 2026, 10:03 PM
SID Score
4.3/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · BDTX
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 1, 2026
BDTX closed at $1.88 after 20 trading sessions, down 10.48% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 1, 2026 | $1.88 | $1.90 | $1.84 | $1.88 | 399.12K |
| Sep 30, 2026 | $1.89 | $1.93 | $1.845 | $1.885 | 551.81K |
| Sep 29, 2026 | $1.84 | $1.89 | $1.825 | $1.87 | 440.2K |
| Sep 28, 2026 | $1.89 | $1.89 | $1.81 | $1.83 | 648.33K |
| Sep 25, 2026 | $1.91 | $1.915 | $1.85 | $1.88 | 378.8K |
| Sep 24, 2026 | $1.90 | $1.915 | $1.83 | $1.89 | 460.23K |
| Sep 23, 2026 | $1.97 | $1.97 | $1.85 | $1.90 | 613.85K |
| Sep 22, 2026 | $1.93 | $1.995 | $1.90 | $1.98 | 744.2K |
| Sep 21, 2026 | $1.96 | $1.97 | $1.91 | $1.95 | 827.32K |
| Sep 18, 2026 | $1.91 | $1.96 | $1.91 | $1.96 | 1.18M |
| Sep 17, 2026 | $1.98 | $2.02 | $1.92 | $1.93 | 665.49K |
| Sep 16, 2026 | $1.97 | $2.0067 | $1.915 | $1.94 | 733.91K |
| Sep 15, 2026 | $2.02 | $2.02 | $1.94 | $1.97 | 301.83K |
| Sep 14, 2026 | $1.98 | $2.04 | $1.97 | $2.03 | 514.16K |
| Sep 11, 2026 | $1.99 | $2.00 | $1.94 | $1.98 | 590.21K |
| Sep 10, 2026 | $2.06 | $2.06 | $1.92 | $1.96 | 677.92K |
| Sep 9, 2026 | $2.09 | $2.1492 | $2.065 | $2.10 | 402.59K |
| Sep 8, 2026 | $2.09 | $2.13 | $2.0719 | $2.10 | 370.04K |
| Sep 4, 2026 | $2.08 | $2.145 | $2.0609 | $2.12 | 324.72K |
| Sep 3, 2026 | $2.15 | $2.1655 | $2.06 | $2.10 | 609.84K |
The latest Smart Investors Daily articles mentioning BDTX.
Company
Market Activity
Research & News
BDTX research
Company profile and research snapshot.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Apr 29, 2026 | BTIG | Buy | — |
| Mar 17, 2026 | Wedbush | Outperform | — |
| Jan 16, 2026 | Piper Sandler | Overweight | — |
| Dec 4, 2025 | Guggenheim | Neutral | — |
| Oct 16, 2025 | Stifel | Buy | — |
No generated briefing is available yet.
Benzinga · May 7, 2026
Black Diamond Therapeutic (NASDAQ:BDTX) reported quarterly losses of $(0.16) per share which missed the analyst consensus estimate of $(0.03) by 433.33 percent. This is a 116.33 percent decrease over earnings of $0.98
Finnhub · May 7, 2026
CAMBRIDGE, Mass. — CAMBRIDGE, Mass. — Black Diamond Therapeutics, Inc. on Thursday reported a first-quarter loss of $9 million, after reporting a profit in the same period a year earlier. The...
Finnhub · May 7, 2026
Oral presentation of silevertinib Phase 2 data in frontline EGFRm NSCLC patients, including preliminary DOR and PFS data, to take place at the 2026 ASCO Annual MeetingFirst patient dosed in the Phase...
Benzinga · Apr 29, 2026
BTIG analyst Robert Burns maintains Black Diamond Therapeutic (NASDAQ:BDTX) with a Buy and raises the price target from $10 to $11.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning BDTX.
